Federal Circuit Decision: When A Typo Costs A Patent Its Priority Date
The Federal Circuit, in Enanta Pharmaceuticals v. Pfizer, held Enanta’s patent could not claim priority to an earlier provisional filing because the provisional described a C2-C12 alkyl range, while the issued claims covered C1-C12. Pfizer’s intervening disclosure of nirmatrelvir (Paxlovid) was treated as prior art, anticipating and invalidating Enanta’s claims under 35 U.S.C. §112.
How this was made
The 30-second read
Why it matters
By treating C2-C12 disclosure as not clearly describing C1-C12, the court prevents Enanta from using the provisional’s priority date. That allows Pfizer’s intervening disclosure of nirmatrelvir to qualify as prior art, anticipating and invalidating the asserted claims.
Market read
This is a precedential patent-priority ruling that can change perceived defensibility of ENTA’s IP and competitive/legal risk around nirmatrelvir-related claims.
What to watch
The article does not quantify remaining enforceable claims, licensing/settlement status, or downstream commercial impact, which can materially change how traders price the decision.
Background
The article frames the case as a written-description and priority-date issue under 35 U.S.C. § 112, where a provisional application must clearly disclose the later-claimed invention.
Ticker impact
Federal Circuit held Enanta’s patent cannot claim priority from its provisional due to a C2-C12 vs C1-C12 drafting mismatch, making Pfizer’s nirmatrelvir prior art.
Potentially negative for ENTA’s litigation/patent value expectations, though magnitude is uncertain without market context.
The decision directly affects Enanta’s ability to rely on earlier filing dates, which can invalidate claims if intervening disclosures qualify as prior art.
Federal Circuit decision found Pfizer’s intervening public disclosure of nirmatrelvir constituted prior art that anticipated and invalidated Enanta’s claims.
Likely modest positive bias for PFE on litigation outcome, but direct financial impact is not quantified in the article.
The article describes a precedential legal holding tied to nirmatrelvir prior art, but provides no damages, settlement, or revenue figures.
Market effects
Highlights drafting-risk in chemical patent prosecution, potentially increasing diligence and litigation sensitivity across pharma/biotech IP portfolios.
US-focused patent-law precedent may influence litigation strategy for US-listed biotech and pharma.
US priority-date standards can affect global patent families and enforcement planning for multinational drug IP.
Counterpoint
Even with priority-date loss, Enanta may still have other claims, continuations, or different patent families not addressed by this specific written-description mismatch.
Key entities
- companyEnanta Pharmaceuticals, Inc.
Federal Circuit held its patent could not rely on its earlier provisional application due to a C2-C12 vs C1-C12 written-description mismatch.
- companyPfizer Inc.
Federal Circuit ruling relied on Pfizer’s intervening public disclosure of nirmatrelvir as prior art that invalidated Enanta’s claims.
- courtFederal Circuit
Issued a precedential opinion emphasizing objective written disclosure over later inventor explanations for priority benefit.
